Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Rollover Study to Evaluate the Long Term Safety and Efficacy of VX 770 in Subjects With Cystic Fibrosis

Trial Profile

An Open-Label, Rollover Study to Evaluate the Long Term Safety and Efficacy of VX 770 in Subjects With Cystic Fibrosis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions; Registrational
  • Acronyms PERSIST
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 08 Oct 2015 According to a Vertex media release, post-hoc analysis of this, STRIVE and ENVISION studies was presented at the 29th Annual North American Cystic Fibrosis Conference
    • 01 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 31 Jul 2014 According to a Vertex Pharmaceuticals media release, the CHMP (European Committee for Medicinal Products for Human Use) has approved the inclusion of data from this study in the product label of Kalydeco.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top